pioglitazone has been researched along with Hyperlipemia in 44 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease." | 9.12 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. ( Dodis, R; Francis, CW; Gerich, JE; Kaba, NK; Lee, M; Messing, S; Mieszczanska, H; Phipps, RP; Schwarz, KQ; Smith, BH; Taubman, MB, 2007) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "To investigate the relationship between insulin resistance, postprandial hyperglycemia, postprandial hyperlipidemia, and oxidative stress in type 2 diabetes, changes in postprandial glucose, triglyceride, and nitrotyrosine levels vs baseline after diet loading were examined in type 2 diabetic patients given pioglitazone (PG) or glibenclamide (GB)." | 5.12 | Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. ( Itoh, Y; Mori, Y; Obata, T; Tajima, N, 2006) |
| "To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease." | 5.12 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. ( Dodis, R; Francis, CW; Gerich, JE; Kaba, NK; Lee, M; Messing, S; Mieszczanska, H; Phipps, RP; Schwarz, KQ; Smith, BH; Taubman, MB, 2007) |
| "Pioglitazone improved insulin resistance and glycemic control, as well as Tg and HDL-C - which suggests that pioglitazone may reduce cardiovascular risk for patients with type 2 diabetes." | 5.09 | The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. ( Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S, 2001) |
| " Search terms used were insulin resistance, diabetes, insulin sensitivity, obesity, cardiovascular disease, metformin, thiazolidinediones, pioglitazone, rosiglitazone, and troglitazone." | 4.82 | Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. ( Henry, RR, 2003) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| " A range of parameters was evaluated including body weight development, plasma levels of total cholesterol, triglycerides (TG), low-density-lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), adiponectin, leptin, glucose, insulin, interleukin-6 (IL-6), atherogenic index (AI) and the coronary risk index (CRI)." | 3.80 | Ficus carica leaf extract modulates the lipid profile of rats fed with a high-fat diet through an increase of HDL-C. ( Benedek, B; Bonnländer, B; Butterweck, V; Joerin, L; Kauschka, M; Pischel, I, 2014) |
| "We examined oxidative stress and metabolic characteristics of the spontaneously hypertensive hyperlipidemic rat (SHHR) when it was fed a high-fat diet and sucrose solution (HFDS) after N(G)-nitro-L-arginine methyl ester ingestion to develop a rat model of metabolic syndrome." | 3.74 | Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution. ( Iwai, S; Kobayashi, S; Kumai, T; Oguchi, K; Okazaki, M; Saiki, R, 2007) |
| "Postprandial hyperlipidaemia in type 2 diabetes is secondary to increased chylomicron production by the enterocytes and delayed catabolism of chylomicrons and chylomicron remnants." | 2.82 | Intestinal lipid absorption and transport in type 2 diabetes. ( Vergès, B, 2022) |
| "Pioglitazone treatment resulted in a significant increase in total (5." | 2.73 | Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. ( Amber, V; Bell, JD; Betteridge, DJ; Fitzpatrick, J; Hamilton, G; Holvoet, P; Hughes, R; Naoumova, RP; North, C; Potter, E; Seed, M; Thomas, EL; Tosi, I, 2007) |
| "Treatment with pioglitazone 30 or 45 mg QD for 16 weeks reduced mean HbA(1c) by 0." | 2.71 | A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. ( Duran, S; Escobar-Jiménez, F; Godin, C; Grossman, LD; Hardin, PA; Hawkins, F; Herz, M; Johns, D; Konkoy, CS; Lochnan, H; Reviriego, J; Tan, MH, 2003) |
| "Overall, 7% of the US population has type 2 diabetes mellitus (T2DM), and among people aged 60 years or older, approximately 20% have T2DM, representing a significant health burden in this age group." | 2.44 | Initiating insulin in patients with type 2 diabetes. ( Aoki, TJ; White, RD, 2007) |
| "Type 2 diabetes is characterised by a gradual decline in glycaemic control and progression from oral glucose-lowering monotherapy to combination therapy and exogenous insulin therapy." | 2.44 | Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. ( Hanefeld, M, 2007) |
| "Patients with type 2 diabetes mellitus frequently have coexistent dyslipidemia, hypertension, and obesity, and are at risk for microvascular and macrovascular disease complications such as myocardial infarction, stroke, retinopathy, and microalbuminuria." | 2.42 | Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. ( Chilton, RJ; Stolar, MW, 2003) |
| "Valvular inflammation triggered by hyperlipidemia has been considered as an important initial process of aortic valve disease; however, cellular and molecular evidence remains unclear." | 1.72 | Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia. ( Ahn, HS; Ann, SJ; Choi, JH; Chung, J; Go, DM; Han, I; Jeong, SC; Kim, DY; Kim, K; Kim, KW; Kim, M; Kim, N; Kim, TK; Lee, HO; Lee, S; Lee, SH; Lee, SP; Oh, GT; Park, J; Park, JH; Park, KS; Park, SE; Park, WY; Shim, D; Woo, SH; Yoon, WK; Zhang, JY, 2022) |
| "Atorvastatin monotherapy was effective at reducing cholesterol (from 4." | 1.62 | Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice. ( Awortwe, C; Joubert, E; Louw, J; Muller, CJF; Patel, O; Rosenkranz, B, 2021) |
| "Treatment with pioglitazone improved serum lipid profile of non-diabetic hyperlipidaemic rats equivalent to that of gemfibrozil." | 1.43 | Pioglitazone improves serum lipid profile in diet induced hyperlipidaemic non diabetic rats. ( Arain, AQ; Chiragh, S; Hussian, M, 2016) |
| "Treatment with pioglitazone decreased the neointimal content of lipid in 20-week-old mice from 50 +/- 6% to 30 +/- 7%, p=0." | 1.33 | Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E. ( Clough, MH; Schneider, DJ; Sobel, BE; Taatjes, DJ; Wadsworth, MP; White, MF, 2005) |
| "In the present study, we assessed hyperlipidemia in Apc-deficient mice, model animals for human familial adenomatous polyposis, and examined the effects of pioglitazone and bezafibrate, respectively, PPARgamma and PPARalpha agonists, on both hyperlipidemia and intestinal polyposis." | 1.32 | Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. ( Itoh, M; Kitamura, T; Niho, N; Noda, T; Shoji, Y; Sugimura, T; Takahashi, M; Wakabayashi, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 32 (72.73) | 29.6817 |
| 2010's | 7 (15.91) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Vergès, B | 2 |
| Lee, SH | 3 |
| Kim, N | 1 |
| Kim, M | 1 |
| Woo, SH | 1 |
| Han, I | 1 |
| Park, J | 1 |
| Kim, K | 2 |
| Park, KS | 1 |
| Shim, D | 1 |
| Park, SE | 1 |
| Zhang, JY | 1 |
| Go, DM | 1 |
| Kim, DY | 1 |
| Yoon, WK | 1 |
| Lee, SP | 1 |
| Chung, J | 1 |
| Kim, KW | 1 |
| Park, JH | 1 |
| Lee, S | 1 |
| Ann, SJ | 1 |
| Ahn, HS | 1 |
| Jeong, SC | 1 |
| Kim, TK | 1 |
| Oh, GT | 1 |
| Park, WY | 1 |
| Lee, HO | 1 |
| Choi, JH | 1 |
| Patel, O | 1 |
| Muller, CJF | 1 |
| Joubert, E | 1 |
| Rosenkranz, B | 1 |
| Louw, J | 1 |
| Awortwe, C | 1 |
| Lee, M | 2 |
| Ovbiagele, B | 1 |
| Saver, JL | 1 |
| Xia, JY | 1 |
| Sun, K | 1 |
| Hepler, C | 1 |
| Ghaben, AL | 1 |
| Gupta, RK | 1 |
| An, YA | 1 |
| Holland, WL | 1 |
| Morley, TS | 1 |
| Adams, AC | 1 |
| Gordillo, R | 1 |
| Kusminski, CM | 1 |
| Scherer, PE | 1 |
| Joerin, L | 1 |
| Kauschka, M | 1 |
| Bonnländer, B | 1 |
| Pischel, I | 1 |
| Benedek, B | 1 |
| Butterweck, V | 1 |
| Sakata, S | 1 |
| Mera, Y | 1 |
| Kuroki, Y | 1 |
| Nashida, R | 1 |
| Kakutani, M | 1 |
| Ohta, T | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Leonard, CE | 1 |
| Han, X | 1 |
| Bilker, WB | 1 |
| Flory, JH | 1 |
| Brensinger, CM | 1 |
| Flockhart, DA | 1 |
| Gagne, JJ | 1 |
| Cardillo, S | 1 |
| Hennessy, S | 1 |
| Polyzos, SA | 1 |
| Bugianesi, E | 1 |
| Kountouras, J | 1 |
| Mantzoros, CS | 1 |
| Hussian, M | 1 |
| Arain, AQ | 1 |
| Chiragh, S | 1 |
| Aoki, TJ | 1 |
| White, RD | 1 |
| Kotake, H | 1 |
| Tan, MH | 3 |
| Herz, M | 1 |
| Johns, D | 1 |
| Reviriego, J | 1 |
| Grossman, LD | 1 |
| Godin, C | 1 |
| Duran, S | 1 |
| Hawkins, F | 1 |
| Lochnan, H | 1 |
| Escobar-Jiménez, F | 1 |
| Hardin, PA | 1 |
| Konkoy, CS | 1 |
| Niho, N | 4 |
| Takahashi, M | 3 |
| Kitamura, T | 1 |
| Shoji, Y | 2 |
| Itoh, M | 1 |
| Noda, T | 1 |
| Sugimura, T | 3 |
| Wakabayashi, K | 4 |
| Stolar, MW | 1 |
| Chilton, RJ | 1 |
| Henry, RR | 1 |
| Takeuchi, Y | 2 |
| Matsubara, S | 1 |
| Yokote, K | 1 |
| Honjo, S | 1 |
| Kobayashi, K | 1 |
| Fujimoto, M | 1 |
| Kawamura, H | 1 |
| Mori, S | 1 |
| Saito, Y | 1 |
| Khan, M | 1 |
| Xu, Y | 1 |
| Edwards, G | 1 |
| Urquhart, R | 1 |
| Mariz, S | 1 |
| Clough, MH | 1 |
| Schneider, DJ | 1 |
| Sobel, BE | 1 |
| White, MF | 1 |
| Wadsworth, MP | 1 |
| Taatjes, DJ | 1 |
| Mukhtar, R | 1 |
| Reckless, JP | 1 |
| Goldberg, RB | 1 |
| Kendall, DM | 1 |
| Deeg, MA | 1 |
| Buse, JB | 1 |
| Zagar, AJ | 1 |
| Pinaire, JA | 1 |
| Khan, MA | 1 |
| Perez, AT | 1 |
| Jacober, SJ | 1 |
| Mutoh, M | 2 |
| Mori, Y | 1 |
| Itoh, Y | 1 |
| Obata, T | 1 |
| Tajima, N | 1 |
| Trivedi, NR | 1 |
| Cong, Z | 1 |
| Nelson, AM | 1 |
| Albert, AJ | 1 |
| Rosamilia, LL | 1 |
| Sivarajah, S | 1 |
| Gilliland, KL | 1 |
| Liu, W | 1 |
| Mauger, DT | 1 |
| Gabbay, RA | 1 |
| Thiboutot, DM | 1 |
| Senba, H | 1 |
| Kawano, M | 1 |
| Kawakami, M | 1 |
| Sakano, K | 1 |
| Yamamoto, M | 1 |
| Sato, H | 1 |
| Mieszczanska, H | 1 |
| Kaba, NK | 1 |
| Francis, CW | 1 |
| Gerich, JE | 1 |
| Dodis, R | 1 |
| Schwarz, KQ | 1 |
| Phipps, RP | 1 |
| Smith, BH | 1 |
| Messing, S | 1 |
| Taubman, MB | 1 |
| Thomas, EL | 1 |
| Potter, E | 1 |
| Tosi, I | 1 |
| Fitzpatrick, J | 1 |
| Hamilton, G | 1 |
| Amber, V | 1 |
| Hughes, R | 1 |
| North, C | 1 |
| Holvoet, P | 1 |
| Seed, M | 1 |
| Betteridge, DJ | 1 |
| Bell, JD | 1 |
| Naoumova, RP | 1 |
| Hanefeld, M | 1 |
| Saiki, R | 1 |
| Okazaki, M | 1 |
| Iwai, S | 1 |
| Kumai, T | 1 |
| Kobayashi, S | 1 |
| Oguchi, K | 1 |
| Tanabe, J | 1 |
| Tamasawa, N | 1 |
| Yamashita, M | 1 |
| Matsuki, K | 1 |
| Murakami, H | 1 |
| Matsui, J | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Suda, T | 1 |
| Wild, RA | 1 |
| Nakagawa, T | 1 |
| Goto, H | 1 |
| Hussein, G | 1 |
| Hikiami, H | 1 |
| Shibahara, N | 1 |
| Shimada, Y | 1 |
| Kadowaki, T | 1 |
| de Souza, CJ | 1 |
| Eckhardt, M | 1 |
| Gagen, K | 1 |
| Dong, M | 1 |
| Chen, W | 1 |
| Laurent, D | 1 |
| Burkey, BF | 1 |
| Rosenblatt, S | 1 |
| Miskin, B | 1 |
| Glazer, NB | 1 |
| Prince, MJ | 1 |
| Robertson, KE | 1 |
| Nakamura, T | 1 |
| Ushiyama, C | 1 |
| Osada, S | 1 |
| Shimada, N | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Ikeda, H | 1 |
| Taketomi, S | 1 |
| Sugiyama, Y | 1 |
| Shimura, Y | 1 |
| Sohda, T | 1 |
| Meguro, K | 1 |
| Fujita, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia[NCT00331487] | Phase 3 | 719 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for pioglitazone and Hyperlipemia
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Intestinal lipid absorption and transport in type 2 diabetes.
Topics: Apolipoprotein B-48; Cholesterol; Chylomicron Remnants; Chylomicrons; Diabetes Mellitus, Type 2; Dip | 2022 |
Initiating insulin in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, C | 2007 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism | 2002 |
[Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].
Topics: Cardiovascular Diseases; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Pioglitazone; | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemod | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resi | 2003 |
Metabolic improvement and abdominal fat redistribution in Werner syndrome by pioglitazone.
Topics: Abdomen; Adipose Tissue; Body Constitution; Female; Glucose; Glucose Tolerance Test; Humans; Hyperli | 2004 |
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hyperlipidemias; Hypoglycemic Agents; Me | 2005 |
Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
Topics: Age Factors; Animals; Benzamides; Bezafibrate; Cyclooxygenase 2; Genes, APC; Humans; Hyperlipidemias | 2006 |
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemi | 2007 |
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic | 2007 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
9 trials available for pioglitazone and Hyperlipemia
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship | 2003 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Topics: Aged; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mell | 2005 |
Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nones | 2006 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlip | 2006 |
Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.
Topics: Adult; Aged; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Fasting; Female; Hemo | 2007 |
Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content.
Topics: Adipose Tissue; Adult; Double-Blind Method; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Li | 2007 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Met | 2001 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperli | 2001 |
22 other studies available for pioglitazone and Hyperlipemia
| Article | Year |
|---|---|
Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Endothelial Cells; Humans | 2022 |
Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.
Topics: Animals; Aspalathus; Atorvastatin; Blood Glucose; Chalcones; Diabetes Mellitus, Experimental; Diabet | 2021 |
Intensive Medical Management to Prevent Large and Small Artery Atherothrombotic Stroke: Time to Expand the Horizon.
Topics: Eicosapentaenoic Acid; Folic Acid; Glucagon-Like Peptide-1 Receptor; Humans; Hyperlipidemias; Hypogl | 2021 |
Acute loss of adipose tissue-derived adiponectin triggers immediate metabolic deterioration in mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Gene Deletion; Gene Expression Prof | 2018 |
Ficus carica leaf extract modulates the lipid profile of rats fed with a high-fat diet through an increase of HDL-C.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat | 2014 |
Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic rat.
Topics: Adipose Tissue, White; Animals; Benzamides; Carrier Proteins; Diabetes Mellitus, Type 2; Drug Therap | 2014 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.
Topics: Aged; Diabetes Mellitus; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2016 |
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.
Topics: Animals; Biomedical Research; Humans; Hyperlipidemias; Hypoglycemic Agents; Ligands; Lipotropic Agen | 2017 |
Pioglitazone improves serum lipid profile in diet induced hyperlipidaemic non diabetic rats.
Topics: Animals; Diet; Hyperlipidemias; Hypoglycemic Agents; Lipids; Pakistan; Pioglitazone; Rats; Rats, Spr | 2016 |
Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Topics: Age Factors; Animals; Bezafibrate; Cholesterol; Fatty Acids, Nonesterified; Genes, APC; Hyperlipidem | 2003 |
Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand.
Topics: Animals; Cholesterol, LDL; Colonic Polyps; Dose-Response Relationship, Drug; Genes, APC; Hyperlipide | 2003 |
Insulin sensitizer affects lipids.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypoglycemic Agents; | 2005 |
Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.
Topics: Administration, Oral; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Hyperlipidemias; Hypoglyc | 2005 |
Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
Topics: Bezafibrate; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperli | 2006 |
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Topics: Animals; Antineoplastic Agents; Carcinogens; Cricetinae; Female; Hyperlipidemias; Ligands; Lipoprote | 2007 |
Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution.
Topics: Animals; Catalase; Dietary Fats; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Glutath | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Chole | 2008 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metfor | 2008 |
Keishibukuryogan ameliorates glucose intolerance and hyperlipidemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; | 2008 |
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
Topics: Adipocytes; Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Cell Division; Cell Size; | 2001 |
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucose Tolerance Test; Hyp | 1990 |